N-Acetyl Cysteine (NAC) for Alzheimer's Disease
Also known as: NAC, Acetylcysteine
Glutathione depletion in AD brain contributes to amyloid-beta toxicity, making NAC supplementation a logical neuroprotective strategy.
Mechanism of Action
NAC restores brain glutathione levels, reduces amyloid-beta-induced oxidative damage, modulates glutamate neurotransmission via cystine-glutamate antiporter, and inhibits microglial inflammatory activation. IV NAC achieves better CNS penetration.
General mechanism: Cysteine prodrug for glutathione synthesis. Direct ROS scavenger. NMDA receptor modulator. NF-κB inhibitor.
Current Evidence
Small clinical studies with IV NAC show improvements in cognitive scores. The NACT-AD trial explored NAC as part of multi-nutrient protocol. Oral bioavailability limits CNS effects.
Clinical Status: Small clinical trials positive for IV NAC. Available as supplement and prescription drug.
Safety Profile
Very safe. GI effects common with oral use. IV administration well-established (acetaminophen protocol). Rare: bronchospasm in asthmatics.
Key Research Questions
- Is IV NAC superior to oral for Alzheimer's neuroprotection?
- Can NAC combination with ALA provide synergistic antioxidant benefit in AD?